Current Edition


Patient-derived Xenograft (PDX) Model: An Evolution in Oncology Drug Study

In order to address shortcomings at the discovery stage in oncology studies, PDX has recently emerged as the upcoming technique. Through the PDX model, original tumour characteristics of humans are simulated in immunodeficient rodents, which eventually offer better predictive insights into the clinical outcome when evaluating the efficacy of novel cancer therapies. Siddhartha Shaurabh of Beroe Inc. explores the adoption of this method across industry participants over different geographies.